These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 30730667)

  • 1. Pembrolizumab (Keytruda°) and metastatic or inoperable melanoma.
    Prescrire Int; 2017 May; 26(182):118-119. PubMed ID: 30730667
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treating metastatic melanoma: Risk management].
    Lebbe C; Robert C
    Ann Dermatol Venereol; 2017 Jan; 144(1):3-5. PubMed ID: 28063593
    [No Abstract]   [Full Text] [Related]  

  • 3. Killing two birds with one stone: response to pembrolizumab in a patient with metastatic melanoma and B-cell chronic lymphocytic leukaemia.
    Arenbergerova M; Fialova A; Arenberger P; Gkalpakiotis S; Jirasek T; Srp A; Novotna A; Frankova H
    J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):e72-e74. PubMed ID: 28833722
    [No Abstract]   [Full Text] [Related]  

  • 4. Persistence of superficial basal cell carcinoma during pembrolizumab treatment for metastatic melanoma.
    Russo I; Filoni A; Alaibac M
    Eur J Dermatol; 2021 Feb; 31(1):99-100. PubMed ID: 33586650
    [No Abstract]   [Full Text] [Related]  

  • 5. Coincident Metastatic Melanoma and Merkel Cell Carcinoma with Complete Remission on Treatment with Pembrolizumab.
    Thiem A; Kneitz H; Schummer P; Herz S; Schrama D; Houben R; Goebeler M; Schilling B; Gesierich A
    Acta Derm Venereol; 2017 Nov; 97(10):1252-1254. PubMed ID: 28761962
    [No Abstract]   [Full Text] [Related]  

  • 6. Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment.
    Gulati N; Carvajal RD; Postow MA; Wolchok JD; Krueger JG
    Exp Dermatol; 2016 Jul; 25(7):553-4. PubMed ID: 27061281
    [No Abstract]   [Full Text] [Related]  

  • 7. Vitiligo-like lesions located over In-transit metastases of malignant melanoma as a clinical marker of complete response to pembrolizumab.
    Gracia-Cazaña T; Padgett E; Hernández-García A; Sánchez-Salas MP
    Dermatol Online J; 2019 Dec; 25(12):. PubMed ID: 32045170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Massive Periocular Squamous Cell Carcinoma With Response to Pembrolizumab (Keytruda).
    Conger JR; Grob SR; Tao J
    Ophthalmic Plast Reconstr Surg; 2019; 35(5):e127. PubMed ID: 30925541
    [No Abstract]   [Full Text] [Related]  

  • 9. Delayed skin toxicity associated with pembrolizumab therapy for metastatic melanoma.
    Arianayagam S; Ieremia E; Matin RN
    Eur J Dermatol; 2019 Jun; 29(3):349-351. PubMed ID: 31389799
    [No Abstract]   [Full Text] [Related]  

  • 10. Resistance to PD-1 blockade in melanoma.
    Burki TK
    Lancet Oncol; 2016 Sep; 17(9):e376. PubMed ID: 27452143
    [No Abstract]   [Full Text] [Related]  

  • 11. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
    Oya K; Nakamura Y; Fujisawa Y; Endo R; Tanaka R; Ishitsuka Y; Maruyama H; Watanabe R; Okiyama N; Fujimoto M
    Eur J Dermatol; 2018 Feb; 28(1):129-130. PubMed ID: 29400284
    [No Abstract]   [Full Text] [Related]  

  • 12. Antiphospholipid Syndrome Following Pembrolizumab Treatment of Stage IIIB Unresectable Melanoma.
    Sanchez A; Montaudie H; Bory P; Belgodere X; Passeron T; Lacour JP; Picard A
    JAMA Dermatol; 2018 Nov; 154(11):1354-1356. PubMed ID: 30326507
    [No Abstract]   [Full Text] [Related]  

  • 13. Advanced melanoma in adults: Pembrolizumab as a treatment option.
    Silvinato A; Bernardo WM; Floriano I
    Rev Assoc Med Bras (1992); 2020 May; 66(2):100-107. PubMed ID: 32428140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
    Lheure C; Hoffmann C; Kramkimel N; Plée J; Franck N; Vanhaecke C; Goldman-Lévy G; Bataillon G; Damotte D; Dupin N; Aractingi S; Grange F; Guégan S
    Acta Derm Venereol; 2019 Jan; 99(1):107-108. PubMed ID: 30176045
    [No Abstract]   [Full Text] [Related]  

  • 15. Acute localised exanthematous pustulosis secondary to pembrolizumab.
    Wang CY; Khoo C; McCormack CJ; Xu W; Pan Y
    Australas J Dermatol; 2017 Nov; 58(4):322-323. PubMed ID: 28691194
    [No Abstract]   [Full Text] [Related]  

  • 16. Novel therapies for unresectable and metastatic melanoma.
    Karimkhani C; Reddy BY; Dellavalle RP; Sundararajan S
    BMJ; 2017 Nov; 359():j5174. PubMed ID: 29191943
    [No Abstract]   [Full Text] [Related]  

  • 17. Diffuse Hepatic Infiltration by Metastatic Melanoma.
    Velázquez HE; Castro-Alonso FJ; Bourlon C; Gabutti A; Gallegos C; Bourlon MT
    Oncology (Williston Park); 2019 Jul; 33(7):. PubMed ID: 31365754
    [No Abstract]   [Full Text] [Related]  

  • 18. Pembrolizumab-Induced Alopecia Areata.
    Elshimy N; Blakeway E; Mitra A
    Skinmed; 2019; 17(2):142-143. PubMed ID: 31145074
    [No Abstract]   [Full Text] [Related]  

  • 19. The use of pembrolizumab for the treatment of metastatic uveal melanoma.
    Kottschade LA; McWilliams RR; Markovic SN; Block MS; Villasboas Bisneto J; Pham AQ; Esplin BL; Dronca RS
    Melanoma Res; 2016 Jun; 26(3):300-3. PubMed ID: 26848796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of amputation by neoadjuvant therapy with pembrolizumab in acrolentiginous melanoma.
    Hansen I; Rünger A; Noebel C; Geidel G; Kött J; Menz A; Hildebrandt L; Schneider SW; Gebhardt C
    J Eur Acad Dermatol Venereol; 2024 Sep; 38(9):e820-e822. PubMed ID: 38421077
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.